HC Wainwright reiterated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV – Free Report) in a research report report published on Friday morning, Benzinga reports. They currently have a $6.00 target price on the stock.
Separately, EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a strong-buy rating in a report on Tuesday, August 27th.
Get Our Latest Stock Analysis on ENLV
Enlivex Therapeutics Price Performance
Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) last released its quarterly earnings data on Friday, August 30th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.06. On average, sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current year.
Institutional Investors Weigh In On Enlivex Therapeutics
An institutional investor recently bought a new position in Enlivex Therapeutics stock. Armistice Capital LLC acquired a new stake in Enlivex Therapeutics Ltd. (NASDAQ:ENLV – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 1,700,571 shares of the company’s stock, valued at approximately $2,415,000. Armistice Capital LLC owned approximately 8.15% of Enlivex Therapeutics at the end of the most recent reporting period. Institutional investors own 1.02% of the company’s stock.
About Enlivex Therapeutics
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.
Read More
- Five stocks we like better than Enlivex Therapeutics
- What is a Special Dividend?
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- What to Know About Investing in Penny Stocks
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.